SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced that a major expansion of its Nucleic Acids Solutions Division (NASD) is complete, enabling the company to manufacture several hundred kilograms of therapeutic oligonucleotides per year. This production capacity allows Agilent to meet customers’ supply needs from preclinical and clinical studies through commercial launch.
